Allos to complete merger with AMAG Pharmaceuticals

Download PDF Copy

Oct 11 2011

Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that it continues to work with AMAG Pharmaceuticals, Inc. towards the completion of their merger, pending stockholder approval and satisfaction of the other conditions to closing described in Allos' definitive proxy statement filed with the SEC on September 15, 2011.

On October 7, 2011, the publicly traded pharmaceutical company that had previously submitted a proposal to acquire Allos for $2.20 per share in cash and stock delivered a letter to Allos withdrawing its revised proposal to acquire Allos. As a result, Allos is no longer providing information to, or engaging in discussions or negotiations with, that company with respect to the revised acquisition proposal or any other acquisition proposal.

Source:

Allos Therapeutics

Posted in: Business / Finance

Tags: Anemia, Bone, Bone Marrow, Cancer, Dehydration, Dyspnea, Folic Acid, Mucositis, Nausea, Neutropenia, Nursing, Pharmaceuticals, Sepsis, Therapeutics, Thrombocytopenia

Comments (0)

Download PDF Copy

Suggested Reading

CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing

CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing

Vaccines targeting chronic diseases show promise in combatting age-related conditions

Vaccines targeting chronic diseases show promise in combatting age-related conditions

Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip

Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip

Study suggests high levels of vitamin B3 breakdown products are linked to higher risk of mortality, heart attacks, and stroke

Study suggests high levels of vitamin B3 breakdown products are linked to higher risk of mortality, heart attacks, and stroke

Study reveals inflammation's role in long COVID's lingering effects

Study reveals inflammation's role in long COVID's lingering effects

Promising candidate medication for preventing and reversing fentanyl-induced overdose

Promising candidate medication for preventing and reversing fentanyl-induced overdose

AmoyDx and CST Expand Existing Partnership for the Development of Companion Diagnostics (CDx) to Support Precision Oncology

AmoyDx and CST Expand Existing Partnership for the Development of Companion Diagnostics (CDx) to Support Precision Oncology

Natural killer cells lead the charge in cancer treatment innovation

Natural killer cells lead the charge in cancer treatment innovation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial